Thérapies ciblées en oncologie endocrinienne: Facteurs pronostiques et prédictifs de réponse

S. Hescot; E. Baudin; F. Borson-Chazot; M. Lombès

doi:10.1016/S0003-4266(13)70017-9

Thérapies ciblées en oncologie endocrinienne: Facteurs pronostiques et prédictifs de réponse

Translated title of the contribution: Targeted therapies, prognostic and predictive factors in endocrine oncology

S. Hescot, E. Baudin, F. Borson-Chazot, M. Lombès

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

Abstract

A better understanding of molecular mechanisms responsible for tumorigenesis has allowed the development of targeted drugs designed to improve the outcome of cancer. In endocrine tumors, several molecules have demonstrated efficacy in terms of progression free survival during phase III trials such as vandetanib and cabozantinib in medullary thyroid carcinoma, sorafenib in differentiated thyroid carcinoma and everolimus or sunitinib for pancreatic neuroendocrine tumors. Rare cancer network has allowed ongoing phase III trials in malignant pheochromocytoma and adrenocortical carcinoma. However, to date no specific predictive biomarker has yet been identified for a personalized cancer medicine. We review recent advances in endocrine oncology concerning molecular targets identification, targeted therapies and predictive or prognostic markers.

Translated title of the contribution	Targeted therapies, prognostic and predictive factors in endocrine oncology
Original language	French
Pages (from-to)	S13-S22
Journal	Annales d'Endocrinologie
Volume	74
Issue number	S1
DOIs	https://doi.org/10.1016/S0003-4266(13)70017-9
Publication status	Published - 1 Oct 2013

Access to Document

10.1016/S0003-4266(13)70017-9

Cite this

@article{cd5be0daa1f64430ae314357af0f7e75,

title = "Th{\'e}rapies cibl{\'e}es en oncologie endocrinienne: Facteurs pronostiques et pr{\'e}dictifs de r{\'e}ponse",

abstract = "A better understanding of molecular mechanisms responsible for tumorigenesis has allowed the development of targeted drugs designed to improve the outcome of cancer. In endocrine tumors, several molecules have demonstrated efficacy in terms of progression free survival during phase III trials such as vandetanib and cabozantinib in medullary thyroid carcinoma, sorafenib in differentiated thyroid carcinoma and everolimus or sunitinib for pancreatic neuroendocrine tumors. Rare cancer network has allowed ongoing phase III trials in malignant pheochromocytoma and adrenocortical carcinoma. However, to date no specific predictive biomarker has yet been identified for a personalized cancer medicine. We review recent advances in endocrine oncology concerning molecular targets identification, targeted therapies and predictive or prognostic markers.",

keywords = "Adrenocortical carcinoma, Malignant pheochromocytoma, Pancreatic neuroendocrine tumor, Predictive marker, Prognostic marker, Targeted therapy, Thyroid carcinoma",

author = "S. Hescot and E. Baudin and F. Borson-Chazot and M. Lomb{\`e}s",

year = "2013",

month = oct,

day = "1",

doi = "10.1016/S0003-4266(13)70017-9",

language = "Fran{\c c}ais",

volume = "74",

pages = "S13--S22",

journal = "Annales d'Endocrinologie",

issn = "0003-4266",

number = "S1",

}

TY - JOUR

T1 - Thérapies ciblées en oncologie endocrinienne

T2 - Facteurs pronostiques et prédictifs de réponse

AU - Hescot, S.

AU - Baudin, E.

AU - Borson-Chazot, F.

AU - Lombès, M.

PY - 2013/10/1

Y1 - 2013/10/1

N2 - A better understanding of molecular mechanisms responsible for tumorigenesis has allowed the development of targeted drugs designed to improve the outcome of cancer. In endocrine tumors, several molecules have demonstrated efficacy in terms of progression free survival during phase III trials such as vandetanib and cabozantinib in medullary thyroid carcinoma, sorafenib in differentiated thyroid carcinoma and everolimus or sunitinib for pancreatic neuroendocrine tumors. Rare cancer network has allowed ongoing phase III trials in malignant pheochromocytoma and adrenocortical carcinoma. However, to date no specific predictive biomarker has yet been identified for a personalized cancer medicine. We review recent advances in endocrine oncology concerning molecular targets identification, targeted therapies and predictive or prognostic markers.

AB - A better understanding of molecular mechanisms responsible for tumorigenesis has allowed the development of targeted drugs designed to improve the outcome of cancer. In endocrine tumors, several molecules have demonstrated efficacy in terms of progression free survival during phase III trials such as vandetanib and cabozantinib in medullary thyroid carcinoma, sorafenib in differentiated thyroid carcinoma and everolimus or sunitinib for pancreatic neuroendocrine tumors. Rare cancer network has allowed ongoing phase III trials in malignant pheochromocytoma and adrenocortical carcinoma. However, to date no specific predictive biomarker has yet been identified for a personalized cancer medicine. We review recent advances in endocrine oncology concerning molecular targets identification, targeted therapies and predictive or prognostic markers.

KW - Adrenocortical carcinoma

KW - Malignant pheochromocytoma

KW - Pancreatic neuroendocrine tumor

KW - Predictive marker

KW - Prognostic marker

KW - Targeted therapy

KW - Thyroid carcinoma

UR - http://www.scopus.com/inward/record.url?scp=84890393930&partnerID=8YFLogxK

U2 - 10.1016/S0003-4266(13)70017-9

DO - 10.1016/S0003-4266(13)70017-9

M3 - Article

C2 - 24356287

AN - SCOPUS:84890393930

SN - 0003-4266

VL - 74

SP - S13-S22

JO - Annales d'Endocrinologie

JF - Annales d'Endocrinologie

IS - S1

ER -

Thérapies ciblées en oncologie endocrinienne: Facteurs pronostiques et prédictifs de réponse

Abstract

Access to Document

Other files and links

Cite this